Choosing Between Donepezil, Galantamine, and Rivastigmine in Alzheimer's Disease

Key Differences Between Medications

The American Academy of Family Physicians recommends that the choice between donepezil, galantamine, and rivastigmine should be based primarily on their administration regimens and side effect profiles, as no head-to-head studies have demonstrated superior efficacy of one agent over another for improving cognitive and global function in Alzheimer's disease patients 1, 2, 3
Donepezil has a once-daily dosing regimen, starting at 5 mg/day, which can be increased to 10 mg/day after 4 weeks, and is generally well-tolerated with mild side effects such as nausea, vomiting, and diarrhea 1, 4
Rivastigmine has a twice-daily dosing regimen, starting at 1.5 mg twice daily, and is associated with more pronounced gastrointestinal side effects, as well as headaches, dizziness, and fatigue, but may be more effective for patients aged 75 years or older 1, 3, 5, 6
Galantamine also has a twice-daily dosing regimen, starting at 4 mg twice daily, and is associated with common side effects such as nausea, vomiting, and diarrhea, but may show advantages over donepezil in patients with MMSE scores between 12-18 1, 3, 8, 6

For patients who would benefit from once-daily dosing, the American Academy of Family Physicians recommends choosing donepezil, while for patients who can reliably take medications twice daily, rivastigmine or galantamine may be considered 1, 4
For patients with hepatic or renal impairment, galantamine should be avoided, and donepezil or rivastigmine preferred, according to the American Academy of Family Physicians 7
For patients aged 75 years or older, rivastigmine may offer additional benefits, as suggested by the American College of Physicians 5, 6

The American Academy of Family Physicians recommends assessing beneficial response after 6-12 months of treatment through physician's global assessment, caregiver reports, neuropsychologic assessments, or evidence of behavioral/functional changes 1, 9
Patients who do not respond to one cholinesterase inhibitor may respond to another, according to the American Academy of Family Physicians 1, 9
The American Academy of Family Physicians suggests considering discontinuation of treatment if side effects develop and do not resolve, adherence is poor, or deterioration continues at the pretreatment rate after 6-12 months 1, 9
Before initiating treatment, the American Academy of Family Physicians recommends communicating the expected modest benefits to patients and families, typically representing a 5-15% benefit over placebo 2, 3
The American College of Physicians notes that while these medications show statistically significant benefits, many of these improvements may not be clinically important for all patients 10, 6